Precision-Based Genomics in Prostate Cancer

Sponsor
National Cancer Institute (NCI) (NIH)
Overall Status
Recruiting
CT.gov ID
NCT04706663
Collaborator
(none)
2,000
Enrollment
14
Locations
69.5
Anticipated Duration (Months)
142.9
Patients Per Site
2.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Background:

Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect how aggressive the disease is.

Objective:

To look at gene mutations in men with prostate cancer as well as the course of their disease to better understand how gene mutations relate to the way the cancer progresses and responds to treatment.

Eligibility:

Adult males 18 and older with prostate cancer who have at least one of the gene mutations researchers want to study and/or have been treated for their cancer and have had complete elimination of their cancer or stable disease for a long time.

Design:

Participants will be screened with a review of their medical records. Their gene test results will be reviewed, if available. They will be asked questions over the phone or in person.

Participants do not need to visit the NIH for this study. But if they visit NIH for another study, their data and test results will be collected. They may give blood and urine samples. They may give leftover tumor samples. These samples will be used to study their genes.

Participants who do not come to NIH on regular basis will be contacted every 6 months by phone or e-mail. They will be asked questions about their health. Data from their medical records will be collected.

Participants will have testosterone and prostate-specific antigen (PSA) tests.

Participants may be invited to NIH to give blood samples for research.

Participants on this study will be followed for life....

Condition or DiseaseIntervention/TreatmentPhase

    Detailed Description

    Background:
    • Prostate cancer is the most common cancer and the second leading cause of death in males in the United States with an estimated 191,930 new cases and 33,330 deaths in 2020.

    • There has been progress in identifying established risk factors for the development of prostate cancer, including genetic predisposition. The study of the molecular genetics of prostate cancer has identified pathogenic variants, such as BRCA1 and BRCA2 (associated with hereditary breast and ovarian cancer syndrome), HOXB13 (associated with hereditary prostate cancer), and DNA mismatch repair (MMR) gene variants (MLH1, MSH2, MSH6, PMS2, and EPCAM) associated with Lynch syndrome.

    • While our understanding of molecular genetics continues to grow, there remains a need to identify additional germline and somatic mutations and alterations that may increase an individual s risk to develop prostate cancer and potentially the aggressiveness of the disease. In studying the following alterations in prostate cancer, in both localized and advanced stages, potential expanded molecular findings may lead to actionable therapeutic targets and biomarker development. A better understanding of molecular genetics in a longitudinal study of subjects with prostate cancer may be helpful for the design of future treatment studies, and to develop a better understanding of the natural history of the disease

    Objectives:
    • To longitudinally evaluate subjects with prostate cancer with known germline and/or somatic variants in PIK3 and/or AKT, PALB2, BRIP1, RAD50, RAD51, RAD54, RB1, SPOP, Wnt/B-catenin pathway, and MMR genes: MLH1, MSH2, MSH6, PMS2, and EPCAM to better understand the natural history of the disease.

    • To longitudinally evaluate subjects with tumor mutational burden-high (TMB-H) prostate cancer [greater than or equal to 10 mutations/megabase (mut/Mb)].

    Eligibility:
    • Subjects with histologically confirmed prostate cancer

    • Must have known germline and/or somatic variants in PIK3 and/or AKT, PALB2, BRIP1, RAD50, RAD51, RAD54, RB1, SPOP, Wnt/B-catenin pathway, and MMR genes: MLH1, MSH2, MSH6, PMS2, and EPCAM and/or TMB-high or be deemed an exceptional responder. NOTE: any platform for genomics testing is acceptable (research or CLIA-certified)

    • Age greater than or equal to 18 years old

    Design:
    • This will be a long-term multi-center study to comprehensively study participants with prostate cancer.

    • Participants will provide clinical information (including medical history, clinical tests, imaging studies and reports, surgical pathology reports, genetic test results).

    • Since long-term follow-up of individuals with prostate cancer is a major feature of the study, local sites intend to maintain active contact with study subjects for as long as possible. Participants will be followed throughout the course of their illnesses, with particular attention to patterns of disease recurrence and progression, response to therapies and duration of responses.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    2000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    A Multi-Center Natural History Study of Precision-Based Genomics in Prostate Cancer
    Actual Study Start Date :
    Sep 14, 2021
    Anticipated Primary Completion Date :
    Jun 30, 2026
    Anticipated Study Completion Date :
    Jun 30, 2027

    Arms and Interventions

    ArmIntervention/Treatment
    Cohort 1

    Subjects with histologically confirmed prostate cancer and genomic testing results

    Cohort 2

    Subjects with histologically confirmed prostate cancer who deemed to be an exceptional responder with or without genomic testing results

    Outcome Measures

    Primary Outcome Measures

    1. natural history of prostate cancer with known germline and/or somatic variants [ongoing]

      clinical presentation, patterns of disease progression, therapeutic response, disease recurrence and participant overall survival

    2. natural history of TMB-H prostate cancer [ongoing]

      clinical presentation, patterns of disease progression, therapeutic response, disease recurrence and participant overall survival

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    • INCLUSION CRITERIA:

    • Subjects with histologically confirmed prostate cancer.

    • Must have known germline and/or somatic variants in PIK3 and/or AKT, PALB2, BRIP1, RAD50, RAD51, RAD54, RB1, SPOP, Wnt/B-catenin pathway, and/or MMR genes: MLH1, MSH2, MSH6, PMS2, and EPCAM and/or TMB-high([defined as greater than or equal to 10 mutations/megabase (mut/Mb)]. NOTE: any platform for genomics testing is acceptable (research or CLIA-certified)

    OR

    • be deemed an exceptional responder. NOTE: an exceptional response is defined as achievement of either a) a complete response, or b) a confirmed partial response in a trial or treatment or a response of exceptionally long duration

    • Age greater than or equal to 18 years old.

    • Ability of subject to understand and the willingness to sign a written informed consent document.

    EXCLUSION CRITERIA:

    -None

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1University of California San DiegoLa JollaCaliforniaUnited States92093
    2University of California at Los AngelesLos AngelesCaliforniaUnited States90095
    3University of California San FranciscoSan FranciscoCaliforniaUnited States94143
    4Lurie Cancer Center at Northwestern UniversityChicagoIllinoisUnited States60611
    5National Institutes of Health Clinical CenterBethesdaMarylandUnited States20892
    6Dana Farber Cancer InstituteBostonMassachusettsUnited States02215
    7University of MichiganAnn ArborMichiganUnited States48109
    8Mount Sinai HospitalNew YorkNew YorkUnited States10029
    9Memorial Sloan Kettering Cancer CenterNew YorkNew YorkUnited States10065
    10Weill Cornell MedicineNew YorkNew YorkUnited States10065
    11Oregon Health Sciences UniversityPortlandOregonUnited States97239
    12Fred Hutchinson Cancer Research CenterSeattleWashingtonUnited States28104
    13Seattle Cancer Care AllianceSeattleWashingtonUnited States98195
    14University of Washington School of MedicineSeattleWashingtonUnited States98195

    Sponsors and Collaborators

    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: William L Dahut, M.D., National Cancer Institute (NCI)

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    National Cancer Institute (NCI)
    ClinicalTrials.gov Identifier:
    NCT04706663
    Other Study ID Numbers:
    • 10000048
    • 000048-C
    First Posted:
    Jan 13, 2021
    Last Update Posted:
    Oct 8, 2021
    Last Verified:
    Oct 5, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by National Cancer Institute (NCI)
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 8, 2021